Epithelioid Sarcoma
Conditions
Brief summary
Prospective Italian study aimed to provide a description of the population affected by Epithelioid Sarcoma (ES)
Detailed description
The present prospective national study aims to provide a description of the population affected by ES, an insight into the natural history of the disease and an answer some on the outstanding questions on its management. Also, it will focus on enhancing any differences between the two ES variants (classical-type and proximal-type) in order gain a better understanding of the disease, tailor the treatment and lastly improve outcome.
Interventions
OTHERTreatment for Epitheloid Sarcoma
Treatment Epitheloid Sarcoma according the disease guideline
Sponsors
Italian Sarcoma Group
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Histological diagnosis of epithelioid sarcoma according to 2014 World Health Organization (WHO) classification, performed on biopsy or surgical specimen 2. Signed informed consent 3. Adequate patient compliance to treatment or follow up 4. No age limit
Exclusion criteria
1. Other malignancies within past 5 years, with exception of carcinoma in situ of the cervix and basocellular skin cancers treated with eradicating intent 2. Impossibility to ensure adequate compliance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Type of treatment given to patients with ES | From diagnosis until the date of death from any cause assessed up to 60 months | Number of chemotherapy treatment received patients affected by ES |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Radiotherapy treatments | From the time of diagnosis and then every 6 months up to 60 months | Number of patients affected by localized ES who received radiotherapy |
| Chemotherapy treatments | From the time of diagnosis and then every 6 months up to 60 months | Number of patients affected by localized ES who received chemotherapy |
| Predictive biomarkers for response | At time of diagnosis and at the time of any progression where a biopsy is performed up to 60 months | Tumor biomarkers expression in tumor tissue of patients affected by ES |
Countries
Italy
Contacts
Primary ContactAnnamaria Frezza, MD
Outcome results
None listed